CGTN
13.10.2020 08:05:04 CEST | Business Wire | Press release
Chinese President Xi Jinping on Monday arrived in south China's Guangdong Province to begin his inspection tour, his 12th domestic visit this year and his third to Guangdong since the 18th National Congress of the Communist Party of China (CPC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201012005890/en/
"Reform and opening-up" remained the keywords during his three visits to Guangdong in 2012, 2018, 2020, respectively.
Read the original article here .
Protecting cultural legacy
During this visit, President Xi visited cultural and historical landmarks in the city of Chaozhou, including an ancient bridge, an ancient gate tower and a street lined with ancient archways, to check on the restoration and protection of cultural relics, the inheritance of intangible cultural heritage and the development of cultural and tourism resources.
The president has always insisted that the protection and exploration of cultural heritage assets must serve a country's development.
In October 2018, Xi stressed that more importance should be attached to preserving history and culture during urban planning and construction during his visit to Xiguan historical and cultural community in the Liwan District of Guangzhou City, Guangdong Province.
During this National Day and Mid-Autumn Festival holiday, the ancient township of Chaozhou received nearly 2 million tourists with a total revenue of some 890 million yuan, with its cultural charm.
The president underscored that the development of tourism should be based on protection and should not be over-commercialized when he visited the Yungang Grottoes, where he learned about historical and cultural heritage protection efforts in north China's Shanxi Province in May this year.
China's reform and opening-up paragon
President Xi also visited Chaozhou Three-Circle (Group) Co., Ltd., an electronic components and communication device manufacturer, checking out the company's indigenous innovation, production and operation.
In 2019, Guangdong's provincial GDP exceeded 10 trillion yuan (about $1.48 trillion). Under the current poverty threshold, over 1.6 million relatively poor people have reached the alleviation standard, a decisive victory in the battle against poverty.
In December 2012, President Xi visited Guangdong's Shenzhen during his first around-the-country tour after he was elected the CPC leader.
Two years ago, when China marked the 40th anniversary of reform and opening-up, he revisited the city and emphasized the need to keep promoting the process of reform and opening-up.
"I come to visit Shenzhen as it marks the 40th anniversary of reform and opening-up to tell the world that China will not stop its reform and opening-up. China will certainly deliver a bigger miracle that draws worldwide attention," he said.
Shenzhen is an important stop during his latest inspection tour to Guangdong Province.
On Wednesday morning, the president will attend a grand gathering celebrating the 40th anniversary of the establishment of the Shenzhen Special Economic Zone.
On August 26, 1980, the 15th meeting of the Standing Committee of the fifth National People's Congress, the national legislature, approved the establishment of special economic zones in Shenzhen, Zhuhai and Shantou in Guangdong Province and Xiamen in Fujian Province.
Over the past four decades, Shenzhen has been transformed from a small fishing village to a modern metropolis with a population of over 13 million.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005890/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom